摘要
目的通过检测控制尿酸合成的限速酶黄嘌呤氧化还原酶活性,进一步探索非酒精性脂肪性肝病发生发展的机制。方法测定261例经腹部超声确诊的非酒精性脂肪性肝病患者和193例健康对照者的血清黄嘌呤氧化还原酶等实验室指标及人体学指标。结果非酒精性脂肪性肝病组血清黄嘌呤氧化还原酶水平显著高于健康对照组,且非酒精性脂肪性肝病合并代谢综合征亚组黄嘌呤氧化还原酶水平显著高于非合并代谢综合征组,差异有统计学意义(P<0.05);逐步回归分析法显示血清黄嘌呤氧化还原酶是非酒精性脂肪性肝病的一个独立危险因素;在非酒精性脂肪性肝病组中,黄嘌呤氧化还原酶水平与代谢考量指数、肝脏损伤指标以及炎症因子呈显著性正相关(P<0.05),且随着合并代谢综合征组分个数的增多,其水平呈逐渐上升趋势。结论血清黄嘌呤氧化还原酶与非酒精性脂肪性肝病的发生发展密切相关。
Objective To detect the activity of rate limiting xanthine oxidoreductase（XOR） controlling uric acid synthesis, so as to explore the development mechanisms of nonalcoholic fatty liver disease（NAFLD）. Methods A total of 261 subjects fulfilled the diagnostic criteria of NAFLD and 193 healthy control participants were enrolled in this cross - sectional study. Serum XOR levels and other clinical and laboratory parameters were measured. Results The serum XOR levels in NAFLD patients was significantly higher than that in the control group, and serum XOR levels in NAFLD subjects with individual components of MS was significantly higher than that in the NAFLD group, the difference was statistically significant （ P 〈 0.05 ） ; stepwise regression showed that serum XOR was an independent risk factor for NAFLD. In subjects with NAFLD, serum XOR levels were significantly and positively correlated with metabolic risk profiles, inflammation indexes and markers of hepatocellular damage （P 〈 0.05 ）, and its levels increased along with the increase of the number of metabolic syndrome components. Conclusion Serum XOR levels are significantly associated with NAFLD.
出处
《中国卫生检验杂志》
CAS
2016年第1期93-97,共5页
Chinese Journal of Health Laboratory Technology
